T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.
|02/13/17||T2 Biosystems Reports Fourth Quarter and Full-Year 2016 Results|
|LEXINGTON, Mass., Feb. 13, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health and deliver a strong economic return to healthcare institutions, today announced operating highlights and financial results for the fourth quarter and year ended December 31, 2016.
Recent Operational and Fourth Quarter Performance Highlights:
Secured commitments in the fourth quarter that will provide access to an estimated... |
|02/06/17||T2 Biosystems to Present at the Leerink Global Healthcare Conference|
|LEXINGTON, Mass., Feb. 06, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that John McDonough, president and chief executive officer, and Shawn Lynch, chief financial officer, are scheduled to attend and present at the Leerink Global Healthcare Conference on Wednesday, February 15, 2017 at 3:30pm ET at the Lotte New York Palace in New York City.
A live, listen-only webcast of the presentation may be accessed by visiting the Events & Presentations section of t... |
|02/03/17||T2 Biosystems Announces 2016 Fourth Quarter and Full-Year Results Release and Conference Call Date|
|LEXINGTON, Mass., Feb. 03, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it will release its 2016 fourth quarter and full-year financial results after the market closes on Monday, February 13, 2017. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Monday, February 13, 2017, to discuss the financial results and other business developments.
Interested parties may access the li... |
|01/30/17||Study Published in the American Journal of Clinical Pathology Highlights Rapid Detection of Platelet Function Using T2MR® Technology|
|Study Shows T2MR’s Sensitive Detection of Platelet Function at Similar or Lower Platelet Counts than Traditional Tests
Paper Provides Novel Insight Into Platelet Biology Not Evident Using Plasma-Based Platelet Aggregation Tests
LEXINGTON, Mass., Jan. 30, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that a new study, “Rapid evaluation of platelet function with T2 magnetic resonanc... |
|Investor Contact Information|
|Data provided by Nasdaq. Minimum 15 minutes delayed.|